Bioengineered ferritin-based lysosome-targeting chimera platform for tumor-targeted therapy - PubMed
14 hours ago
- #tumor-therapy
- #ferritin
- #LYTAC
- Development of a modular LYTAC platform using human heavy chain ferritin (HFn) for tumor-targeted therapy.
- HFn-LYTACs efficiently degrade proteins like EGFR, HER2, and PD-L1 via TfR1-dependent endocytosis and multivalent ligand effects.
- In vivo studies show HFn-LYTACs inhibit tumor growth with favorable safety profiles.
- The platform offers a versatile and efficient strategy for degrading membrane proteins in cancer therapy.